DelveInsight's Interleukin-17 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes ...

The submission is supported by four Phase III clinical trials, which showed that icotrokinra demonstrated significant skin ...

The Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for deucravacitinib for the treatment of adults with active psoriatic arthritis (PsA).

LP usually appears as small purple or red irritated bumps on the scalp and in some cases, it can cause hair loss. On other ...

China: A recent Mendelian randomization (MR) study has revealed that psoriasis may be inversely associated with uterine ...

SHELTON, CT / ACCESS Newswire / July 21, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.: NNVC ) (the ...

Oruka Therapeutics Inc (NASDAQ:ORKA) saw its stock rise 6.6% after revealing that the U.S. Food and Drug Administration (FDA) has approved its investigational new drug (IND) application to begin a ...

Icotrokinra is a first-in-class targeted oral peptide that blocks interleukin (IL) 23 and its receptor, which plays a key role in the inflammatory response in plaque psoriasis.

While Stelara is used in fewer indications than Humira, it commands a large market share in its therapeutic areas, most ...

Investing.com -- Oruka Therapeutics Inc (NASDAQ: ORKA) stock rose 6.6% after the company announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) ...

U.S. Dermatology Partners, one of the leading dermatology groups in the country, is pleased to announce the opening of its ...

Inference-based guidance supports using systemic psoriasis treatments in cancer patients on immune checkpoint inhibitors ...